Huahaipharm's subsidiary, Ruixiqi's Bevacizumab Injection marketing authorization application has been accepted
I'm PortAI, I can summarize articles.
Huahaipharm's subsidiary, Huaotai, recently received the acceptance notice for the marketing authorization application of Reciqi Bai Injection from the National Medical Products Administration. This drug is used for the treatment of adult generalized pustular psoriasis (GPP) and is the first domestically developed anti-IL-36R antibody, demonstrating good safety and efficacy
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments